drugset
drugset / Trial / NCT02047214

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

NCT02047214 ↗

Phase 2 Terminated 17 enrolled Cortice Biosciences, Inc.
SequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

Timeline

Start
2014-01
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TPI 287 Small molecule 120 mg/m2 Intravenous
Subject TPI 287 Small molecule 130 mg/m2 Intravenous
Subject TPI 287 Small molecule 140 mg/m2 Intravenous
Subject TPI 287 Small molecule 160 mg/m2 Intravenous
Subject TPI 287 Small molecule 170 mg/m2 Intravenous
Subject TPI 287 Small molecule 180 mg/m2 Intravenous
Background Bevacizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

glioblastoma